Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ChemoCentryx, Inc. - Common Stock (NQ:CCXI)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ChemoCentryx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Futures Slide As Soaring Oil Nears $85
While cash bonds may be closed, one can easily extrapolate where they would be trading based on TSY futures which are currently trading at a 1.65% equivalent. 
Via Talk Markets
Topics Bonds
Exposures Debt Markets
10 Biggest Price Target Changes For Monday
Keybanc lifted Netflix, Inc. (NASDAQ: NFLX) price target from $645 to $670. Netflix shares rose 0.1% to $633.00 in pre-market trading. JMP Securities raised ServiceNow, Inc. (... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down; Crude Oil Jumps 2%
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Nasdaq dropped around 75 points in the previous session. Futures for the Dow Jones Industrial... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
35 Biggest Movers From Friday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
Via Benzinga
Exposures Product Safety
5 Stocks To Watch For October 11, 2021
Some of the stocks that may grab investor focus today are: Mandiant Inc (NASDAQ: MNDT) reported the completion of divestiture of its FireEye Products unit to McAfee Enterprise... 
Via Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
Why ChemoCentryx Stock Skyrocketed Today
Investors are excited about the biotech's game-changing new drug. 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.24% to 34,835.06 while the NASDAQ fell 0.13% to 14,635.04. The S&P also rose, gaining 0.13% to 4,405.69. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks
The broader market was mixed on Friday. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge
Midway through trading Friday, the Dow traded down 0.06% to 34,734.52 while the NASDAQ fell 0.25% to 14,617.60. The S&P also fell, dropping 0.08% to 4,396.09. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
EXCLUSIVE: ChemoCentryx Plans To Start Phase 3 Avacopan Trial In Chronic Skin Disorder In 2022
After a tight advisory committee vote back in May tilted just slightly in favor of approving ChemoCentryx Inc's (NASDAQ: CCXI) avacopan, the FDA has cleared the drug... 
Via Benzinga
Exposures Product Safety
28 Stocks Moving In Friday's Mid-Day Session
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
Exposures Product Safety
CCXI Stock: The Big FDA News That Has ChemoCentryx Shares Skyrocketing 60%
CCXI stock is making its investors very happy this morning with some huge gains. It's receiving FDA approval for a rare disease treatment. 
Via InvestorPlace
Exposures Product Safety
Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September
Following the market opening Friday, the Dow traded up 0.12% to 34,796.95 while the NASDAQ rose 0.09% to 14,667.44. The S&P also rose, gaining 0.16% to 4,406.93. The U.S. has... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The company's market cap stands at $2.4 billion. eFFECTOR... 
Via Benzinga
Why Did ChemoCentryx Shares Soar 70% On Friday Premarket?
The FDA has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Superior Drilling Products, Inc. (NYSE: SDPI) shares rose 60.6% to close at $1.75 on Thursday after jumping over 23% on Wednesday. The company, last month, reported Q2... 
Via Benzinga
ChemoCentryx Stock Needs To Hold At Support Or It May Slide Lower
ChemoCentryx Inc (NASDAQ: CCXI) shares are trading lower Thursday, although there looks to be no company-evident news to explain the jump in share price. The stock was... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Progenity (NASDAQ:PROG) stock increased by 21.06% to $1.31 during Thursday's regular session. The current volume of 70.4 million shares is 943.37% of Progenity... 
Via Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 55% to $13.00. Paltalk engaged ClearThink to lead expanded investor relations program. Farmmi, Inc. (NASDAQ: FAMI) jumped 45.5... 
Via Benzinga
Why Are ChemoCentryx's Shares Trading Higher Today?
ChemoCentryx Inc's (NASDAQ: CCXI) partner Kissei Pharmaceutical Co Ltd has received approval from the Japanese Ministry of Health, Labor, and Welfare... 
Via Benzinga
22 Stocks Moving in Friday's Pre-Market Session
Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 42% to $15.24 in pre-market trading. The company’s shares jumped around 65% over the previous month. vTv Therapeutics Inc... 
Via Benzinga
2 Growth Stocks That Could Take Off Before the End of the Year
They've been struggling thus far in 2021, but things could turn around quickly for these companies. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.